Literature DB >> 28928275

Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.

Tianzhou Wu1, Jiang Li1, Li Shao1, Jiaojiao Xin1, Longyan Jiang1, Qian Zhou1, Dongyan Shi1, Jing Jiang1, Suwan Sun1, Linfeng Jin1, Ping Ye1, Lingling Yang1, Yinyun Lu1, Tan Li1, Jianrong Huang1, Xiaowei Xu1, Jiajia Chen1, Shaorui Hao1, Yuemei Chen1, Shaojie Xin2, Zhiliang Gao3, Zhongping Duan4, Tao Han5, Yuming Wang6, Jianhe Gan7, Tingting Feng7, Chen Pan8, Yongping Chen9, Hai Li10, Yan Huang11, Qing Xie12, Shumei Lin13, Lanjuan Li1, Jun Li1.   

Abstract

OBJECTIVE: The definition of acute-on-chronic liver failure (ACLF) based on cirrhosis, irrespective of aetiology, remains controversial. This study aimed to clarify the clinicopathological characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) in a prospective study and develop new diagnostic criteria and a prognostic score for such patients.
DESIGN: The clinical data from 1322 hospitalised patients with acute decompensation of cirrhosis or severe liver injury due to chronic hepatitis B (CHB) at 13 liver centres in China were used to develop new diagnostic and prognostic criteria.
RESULTS: Of the patients assessed using the Chronic Liver Failure Consortium criteria with the exception of cirrhosis, 391 patients with ACLF were identified: 92 with non-cirrhotic HBV-ACLF, 271 with cirrhotic HBV-ACLF and 28 with ACLF with cirrhosis caused by non-HBV aetiologies (non-HBV-ACLF). The short-term (28/90 days) mortality of the patients with HBV-ACLF were significantly higher than those of the patients with non-HBV-ACLF. Total bilirubin (TB) ≥12 mg/dL and an international normalised ratio (INR) ≥1.5 was proposed as an additional diagnostic indicator of HBV-ACLF, and 19.3% of patients with an HBV aetiology were additionally diagnosed with ACLF. The new prognostic score (0.741×INR+0.523×HBV-SOFA+0.026×age+0.003×TB) for short-term mortality was superior to five other scores based on both discovery and external validation studies.
CONCLUSIONS: Regardless of the presence of cirrhosis, patients with CHB, TB ≥12 mg/dL and INR ≥1.5 should be diagnosed with ACLF. The new criteria diagnosed nearly 20% more patients with an HBV aetiology with ACLF, thus increasing their opportunity to receive timely intensive management. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Hepatitis B; Liver Cirrhosis; Liver Failure

Mesh:

Substances:

Year:  2017        PMID: 28928275     DOI: 10.1136/gutjnl-2017-314641

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  76 in total

1.  Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Guojun Shen; Shuilin Sun; Jie Huang; Haohui Deng; Ying Xu; Zhanhui Wang; Xiong Tang; Xiaodong Gong
Journal:  Hepatol Int       Date:  2019-12-23       Impact factor: 6.047

2.  sTim-3 alleviates liver injury via regulation of the immunity microenvironment and autophagy.

Authors:  Ying Yang; Gaoxiang Ying; Fengtian Wu; Zhi Chen
Journal:  Cell Death Discov       Date:  2020-07-22

3.  Validation of non-invasive tools in predicting HBV-related acute-on-chronic liver failure.

Authors:  Ting Wu; Tao Chen; Qin Ning
Journal:  Hepatol Int       Date:  2021-06-17       Impact factor: 6.047

4.  Acute-on-chronic liver failure.

Authors:  Rahul Kumar; Gautam Mehta; Rajiv Jalan
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

5.  Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.

Authors:  Daxian Wu; Sainan Zhang; Zhongyang Xie; Ermei Chen; Qunfang Rao; Xiaoli Liu; Kaizhou Huang; Jing Yang; Lanlan Xiao; Feiyang Ji; Zhengyi Jiang; Yalei Zhao; Xiaoxi Ouyang; Danhua Zhu; Xiahong Dai; Zhouhua Hou; Bingjie Liu; Binbin Deng; Ning Zhou; Hainv Gao; Zeyu Sun; Lanjuan Li
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.

Authors:  Xiaogang Xiang; Dechun Feng; Seonghwan Hwang; Tianyi Ren; Xiaolin Wang; Eszter Trojnar; Csaba Matyas; Ruidong Mo; Dabao Shang; Yong He; Wonhyo Seo; Vijay H Shah; Pal Pacher; Qing Xie; Bin Gao
Journal:  J Hepatol       Date:  2019-11-29       Impact factor: 25.083

7.  Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region.

Authors:  Tao Chen; Zhongyuan Yang; Ashok Kumar Choudhury; Mamun Al Mahtab; Jun Li; Yu Chen; Soek-Siam Tan; Tao Han; Jinhua Hu; Saeed S Hamid; Lee Guan Huei; Hasmik Ghazinian; Yuemin Nan; Yogesh K Chawla; Man-Fung Yuen; Harshad Devarbhavi; Akash Shukla; Zaigham Abbas; Manoj Sahu; A K Dokmeci; Laurentias A Lesmana; Cosmas Rinaldi A Lesmana; Shaojie Xin; Zhongping Duan; Wei Guo; Ke Ma; Zhongwei Zhang; Qiuyu Cheng; Jidong Jia; B C Sharma; Shiv Kumar Sarin; Qin Ning
Journal:  Hepatol Int       Date:  2019-10-24       Impact factor: 6.047

8.  A nomogram to predict survival in patients with acute-on-chronic hepatitis B liver failure after liver transplantation.

Authors:  Liang Chen; Jiebin Zhang; Tongyu Lu; Jianye Cai; Jun Zheng; Jia Yao; Shuhong Yi; Hua Li; Guihua Chen; Hui Zhao; Yingcai Zhang; Yang Yang
Journal:  Ann Transl Med       Date:  2021-04

9.  Identification of a Potential miRNA-mRNA Regulatory Network Associated With the Prognosis of HBV-ACLF.

Authors:  Shanshan Ma; Zhongyang Xie; Lingjian Zhang; Ya Yang; He Jiang; Xiaoxi Ouyang; Yalei Zhao; Qiuhong Liu; Xiaowei Xu; Lanjuan Li
Journal:  Front Mol Biosci       Date:  2021-04-28

10.  Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study.

Authors:  Xin-Yu Sheng; Fei-Yan Lin; Jian Wu; Hong-Cui Cao
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.